Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Next Previous
Trial Profile

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pyrotinib (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 07 Jun 2022 Results of pooled analysis from (NCT01937689,NCT02361112,NCT02422199,NCT03080805) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2020 Results (N=63), pooled analysis of three trials, assessing efficacy of pyrotinib plus capecitabine pts with HER2-positive, trastuzumab-resistant relapsed or metastatic breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2020 Results of pooled analysis investigating the efficacy of pyrotinib plus capecitabine as first-line treatment in patients with HER2-positive relapsed or metastatic breast cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top